Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 377

Sort by

Sort Order Select

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood blood.2025029234.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Journal Articles

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood blood.2025028833.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy

Blood blood.2024025755.

https://doi.org/10.1182/blood.2024025755

Published: 2025

Includes: Supplemental data

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

Blood (2024) 144 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2024-198455

Published: 2024

Journal Articles

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Brandon S. Imber, Anna Brosoff, Emma Roszak, Devin McAvoy, Kinga K. Hosszu, Alexander P. Boardman, Parastoo B Dahi, Gunjan L. Shah, Michael Scordo, Jae H. Park, Miguel-Angel Perales, Gilles Salles, Maria Lia Palomba, Joachim Yahalom

Blood (2024) 144 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2024-210156

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Blood (2024) 144 (Supplement 1): 781.

https://doi.org/10.1182/blood-2024-200915

Published: 2024

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT

Madhumitha Rangesa, Anqi Dai, Peter Adintori, William Jogia, Teng Fei, Nicholas Waters, Mirae Baichoo, Annamaria Ballweg, Sukanya Sahu, Jonas Schluter, Marcel R.M. van den Brink, Jonathan U. Peled, Miguel-Angel Perales

Blood (2024) 144 (Supplement 1): 4943.

https://doi.org/10.1182/blood-2024-210447

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

Joseph P. McGuirk, Mark Fesen, Scott D. Ramsey, Rony Abou-Jawde, Anthony Proli, Hil Hsu, Anik R Patel, Miguel-Angel Perales, Blythe Adamson, Jiarui Fu, Jeremy Snider

Blood (2024) 144 (Supplement 1): 2367.

https://doi.org/10.1182/blood-2024-208283

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only